|
HALO | Halozyme Therapeutics, Inc. |
|
|
HALO | Halozyme Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.01 |
| Leverage | 98.07% |
| Market Cap | $ 8.1B |
| PE | 25.24 |
| Dividend Yield | 0.00% |
| Profit | $ 321.4m |
| Margin | 22.77% |
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.